20/20 Biolabs, Inc. (AIDX): R&D Expense

Annual figures by period end, from SEC filings.

$592.6K

Year ended 2025-12-31

$672.7K

Trailing 12 months to 2026-06-30

2024-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$592.6K	-53.0%	2026-03-31, From 2025-01-01
2024-12-31	$1.26M	n/a	2026-03-31, From 2024-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Testing Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
20/20 Biolabs, Inc. (AIDX)	2025-12-31	$592.6K	-53.0%
NeoGenomics Inc (NEO)	2025-12-31	$37.08M	+19.0%

Compare AIDX, NEO side by side · Screen every company in Services-Testing Laboratories ↗